SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -22.49M | -18.87M | -16.86M | 45.45M | -10.11M |
| Total Depreciation and Amortization | 834.30K | 752.70K | 763.30K | 765.50K | 773.70K |
| Total Amortization of Deferred Charges | -- | -- | 261.10K | -- | -- |
| Total Other Non-Cash Items | 8.57M | 5.91M | 6.38M | -60.88M | 1.25M |
| Change in Net Operating Assets | 3.24M | -2.06M | -7.32M | 1.62M | 942.50K |
| Cash from Operations | -9.84M | -14.27M | -16.78M | -13.05M | -7.15M |
| Capital Expenditure | -1.59M | -983.30K | -933.20K | -- | -- |
| Sale of Property, Plant, and Equipment | 800.00 | 2.20K | 0.00 | 0.00 | 500.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.30M | -64.67M | -773.00K | -129.87M | 5.20M |
| Cash from Investing | -4.88M | -65.65M | -1.71M | -129.87M | 5.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -38.60K | -37.40K | -36.70K | -36.00K | -174.10K |
| Issuance of Common Stock | 2.41M | 89.96M | 0.00 | 168.73M | 100.00 |
| Repurchase of Common Stock | -4.40K | -4.60K | -4.30K | -4.90K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -800.00 | -- | -- |
| Cash from Financing | 2.36M | 89.92M | -41.70K | 168.69M | -174.00K |
| Foreign Exchange rate Adjustments | 107.30K | 14.70K | -397.90K | -37.50K | 179.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.25M | 10.02M | -18.92M | 25.73M | -1.95M |